Anzeige
Mehr »
Samstag, 11.04.2026 - Börsentäglich über 12.000 News
0,01% von 1 BILLIONEN USD = 100 MILLIONEN USD - Und UberDoc ist gerade erst an die Börse gegangen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LGJ2 | ISIN: FR0004163111 | Ticker-Symbol: XUP
Xetra
18.03.26 | 17:35
8,710 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENFIT SA Chart 1 Jahr
5-Tage-Chart
GENFIT SA 5-Tage-Chart
RealtimeGeldBriefZeit
8,6008,75010.04.
8,6108,74010.04.
Xetra-Umsätze heute
UhrzeitAktienkursStück

Keine Umsätze verfügbar.

Tagesumsatz Xetra-
0

 Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.

Aktuelle News zur Aktie GENFIT SA

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiGENFIT S.A.: GENFIT Announces Publication of the 2025 Universal Registration Document3
GENFIT Aktie jetzt für 0€ handeln
02.04.GENFIT S.A.: GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update1.3862025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million...
► Artikel lesen
10.03.Genfit Receives FDA Orphan Drug Designation For NTZ In Acute-on-Chronic Liver Failure16
09.03.GENFIT S.A.: GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF483FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapiesNTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical...
► Artikel lesen
26.02.GENFIT S.A.: GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update656Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen's strong performance with Iqirvo® in PBC (>$200M net sales in...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Das könnte Sie auch interessieren
ZeitAktuelle NachrichtenMedien
FrMetaVia Inc.: MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026...
► Artikel lesen
FreXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything PodcastLOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals...
► Artikel lesen
FrXFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.04.2026The following instruments on Boerse Frankfurt do have their last trading day on 10.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.04.2026.ISIN NameAU000000ICI5...
► Artikel lesen
FrWeekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno TherapeuticsTHOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations...
► Artikel lesen
FrEQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionEQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide...
► Artikel lesen